AstraZeneca Invests $2B in Summit Therapeutics at $18.36/Share Premium

summarizeSummary

AstraZeneca is investing $2 billion in Summit Therapeutics via convertible preferred stock priced at a premium, alongside a clinical collaboration to combine ivonescimab with AstraZeneca's ADC portfolio.

check_boxKey Events · Financing and Capital Events · SMMT

• AstraZeneca $2B Strategic Equity Investment

  AstraZeneca Holdings B.V. agreed to purchase 108,955.3686 shares of newly designated Class A Convertible Preferred Stock for $2.0 billion, priced at $18,356.14 per preferred share — equivalent to $18.3561 per common share, a premium to Summit's closing price on September 28, 2026.

• Conversion Terms and Dilution

  Each preferred share converts into 1,000 common shares at a 1:1,000 ratio, yielding approximately 108,955,369 common shares upon full conversion. Conversion requires HSR clearance and shareholder approval of an authorized share increase to at least 1.25 billion shares by December 31, 2026.

• Clinical Collaboration with AstraZeneca

  Summit entered a clinical trial collaboration to evaluate sonesitatug vedotin (sone-ve) in combination with ivonescimab in multiple GI cancer settings, with each company contributing its compound and sharing study costs. A non-binding MOU also covers combining ivonescimab with AstraZeneca's broader ADC portfolio.

• Investor Rights and Lock-Up

  AstraZeneca received preemptive rights on future equity issuances, rights to participate in third-party acquisition proposals, and a one-year lock-up on the preferred shares and underlying common stock. Summit must file a resale registration statement within 60 days of closing.

auto_awesomeAnalysis · SMMT · Life Sciences

AstraZeneca is buying $2 billion of newly created convertible preferred stock at $18.36 per common share equivalent — a premium to Summit's closing price on the deal date. The investment converts into roughly 109 million common shares, a highly dilutive issuance for existing holders, but it also removes the near-term survival risk flagged in Summit's Q2 10-Q going-concern warning. The deal comes with a clinical collaboration pairing ivonescimab with AstraZeneca's sone-ve ADC in GI cancers, plus a non-binding MOU to test ivonescimab with AstraZeneca's broader ADC portfolio. Summit must get shareholder approval to raise authorized shares to at least 1.25 billion by December 31, 2026, or face a cash redemption of the preferred stock. This is a thesis-altering event: a major pharma validating ivonescimab with real capital and a development partnership, while simultaneously resetting Summit's capital structure.